Synapse - Works

Results (115605)

Individualized treatment-adjusted risk stratification in newly diagnosed multiple myeloma

Meeting Abstract

Maura, F.; Rajanna, A. R.; Derkach, A.; Ziccheddu, B.; Weinhold, N.; Maclachlan, K. H.; Diamond, B.; Davies, F. E.; Boyle, E.; Walker, B. A.; more...
Blood (2022)

Fulltext@MSK | Save

Three-year update from the optic trial: A dose-optimization study of 3 starting doses of ponatinib

Meeting Abstract

Cortes, J. E.; Deininger, M. W.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
Blood (2022)

Fulltext@MSK | Save

Clinical benefit associated with biomarker changes indicative of disease modification in patients with myelofibrosis treated with the BET inhibitor pelabresib as monotherapy or in combination with ruxolitinib

Meeting Abstract

Scandura, J.; Verstovsek, S.; Kremyanskaya, M.; Talpaz, M.; Rampal, R. K.; Vannucchi, A.; Gupta, V.; Palandri, F.; Patriarca, A.; Bose, P.; more...
Blood (2022)

Fulltext@MSK | Save

Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R(2)) for first-line treatment of follicular lymphoma: Initial results from phase 1/2 trial

Meeting Abstract

Falchi, L.; Leslie, L. A.; Belada, D.; Kopeckova, K.; Offner, F.; Brody, J.; Canales, M.; García-Sancho, A. M.; Nijland, M.; Andersson, P. O.; more...
Blood (2022)

Fulltext@MSK | Save

Age, albumin, and LDH predict outcome of patients with limited stage peripheral T cell lymphoma: A prognostic model developed on 244 cases enrolled in the T cell project 1 by the International T Cell Project Network

Meeting Abstract

Hapgood, G.; Civallero, M.; Stepanishyna, Y.; Vose, J. M.; Cabrera, M. E.; Advani, R. H.; Pileri, S. A.; Manni, M.; Horwitz, S. M.; Foss, F. M.; more...
Blood (2022)

Fulltext@MSK | Save

CNS relapse in T-cell lymphoma index: A risk score to predict central nervous system relapse in patients with T-cell lymphomas

Meeting Abstract

Bhansali, R. S.; Ellin, F.; Cao, M.; Relander, T.; Li, W.; Long, Q.; Ganesan, N.; Stuver, R.; Horwitz, S. M.; Wudhikarn, K.; more...
Blood (2022)

Fulltext@MSK | Save

Predictors of long-term outcome in TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplant after first- or second-line therapy: Results from the consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Meeting Abstract

Badar, T.; Atallah, E. L.; Shallis, R. M.; Saliba, A. N.; Stahl, M. F.; Bewersdorf, J. P.; Grenet, J.; Patel, A. A.; Abaza, Y.; Murthy, G. S. G.; more...
Blood (2022)

Fulltext@MSK | Save

Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update

Meeting Abstract

Falchi, L.; Abrisqueta, P.; Nijland, M.; Leppä, S.; Hutchings, M.; Holte, H.; Merryman, R. W.; Lugtenburg, P.; de Vos, S.; Cheah, C. Y.; more...
Blood (2022)

Fulltext@MSK | Save

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study

Meeting Abstract

Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
Blood (2022)

Fulltext@MSK | Save

Predictive value of minimal residual disease on efficacy of rituximab maintenance in mantle cell lymphoma: Results from the European MCL Elderly trial

Meeting Abstract

Hoster, E.; Delfau, M. H.; Macintyre, E. A.; Jiang, L. M.; Stilgenbauer, S.; Vehling-Kaiser, U.; Salles, G.; Thieblemont, C.; Tilly, H.; Kanz, L.; more...
Blood (2022)

Fulltext@MSK | Save